Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Abroad (travel likely)RecruitingPHASE3
Conditions
Cardiogenic Shock
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
CHR Metz - Thionville, Ars-Laquenexy, France
Contact: Study coordinator (Guillaume LOUIS, MD) · guillaume.louis@chr-metz-thionville.fr · +33 3 87 55 31 31Contact: Principal Investigator (Guillaume LOUIS, MD)CHU de Besançon, Besançon, France
Contact: Study coordinator (Hadrien WINISZEWSKI, Md PhD) · hwiniszewski@chu-besancon.fr · +33 3 81 66 81 66.Contact: Principal Investigator (Hadrien WINISZEWSKI, MD PhD)CHU de Dijon Bourgogne, Dijon, France
Contact: Study coordinator (Jean Pierre QUENOT, MD)Contact: Principal Investigator (Jean Pierre QUENOT, MD PhD)CHU Lille, Lille, France
Contact: Study coordinator (LEMESLE Gilles, MD PhD) · gilles.lemesle@chru-lille.fr · +33 3 20 44 59 62Contact: Principal Investigator (Gilles LEMESLE, MD pHD)CHU Reims, Reims, France
Contact: Study coordinator (Bruno MOURVILLIER, MD PhD)Contact: Principal Investigator (Bruno MOURVILLIER, MD PhD)Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Contact: Study coordinator (Hamid MERDJI, MD PhD) · hamid.merdji@chru-strasbourg.fr · +33 3 88 11 67 68Contact: Principal Investigator (Hamid MERDJI, MD PhD)CHRU de NANCY - réanimation médicale, Vandœuvre-lès-Nancy, France
Contact: Principal Investigator (Antoine KIMMOUN, MD PhD)Chru Nancy - Usic, Vandœuvre-lès-Nancy, France
Contact: Principal Investigator (Batric POPOVIC, MD pHD)
Study leads
Nicolas GIRERD, MD PhD
Study Chair
CHRU of NANCY